Medipharm Labs Corp T.LABS

Alternate Symbol(s): MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.

TSX:LABS - Post by User

Medipharm Labs Corp > ANDA - 505(b)(2)

<< Previous

Bullboard Posts

Next >>

Comment by Solid1on Sep 04, 2024 4:24am

101 Views

Post# 36207464

RE:RE:RE:RE:RE:RE:ANDA - 505(b)(2)

Jazz had exclusive rights to the active ingredient CBD for five years, this exclusivity expired in September 2023 (i.e. no patent). CBD cannot be patented. The patents that Jazz currently holds relate to specific treatment methods in the field of epilepsy.

So if there is a new treatment option, it can get marketing authorisation...because the active ingredient CBD is no longer exclusive. Quite simply

<< Previous

Bullboard Posts

Next >>

Quantum eMotion leaps by 20 per cent after Becton Dickinson deal